Navigation Links
Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors

LONDON, Sept. 25 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a private biopharmaceutical company focusing on first-in-class, novel non-steroidal anti-inflammatory drugs, today announced it has appointed Dr. Johnson Lau and Dr. David Sidransky to its board of directors.

Dr. Johnson Lau (MBBS, MD, FRCP) brings a wealth of experience from the medical, pharmaceutical and corporate fields, having a distinguished background in both academic medicine and executive-level management of pharmaceutical and biotechnology companies. Dr. Lau previously served Schering-Plough, ICN Pharmaceuticals and its subsidiary Ribapharm, and is currently a senior advisor to Novartis. He was formerly a managing director of healthcare investment banking of Roth Capital Partners. Dr. Lau also serves as a member of the board of directors of Chelsea Therapeutics, VioQuest Pharmaceuticals, XenoBiotic Laboratories and Kinex Pharmaceuticals. Dr. Lau is a Fellow of the Royal College of Physicians of the United Kingdom. He received both his medical degree and doctoral degree from the University of Hong Kong.

Dr. David Sidransky (MD) is the director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and is also a professor of oncology, otolaryngology-head and neck surgery, cellular and molecular medicine, urology, and genetics and pathology at the university. He is currently vice-chairman of the board of directors of ImClone Systems, lead independent chairman at Alfacell Inc. and serves on the board of directors of Zila Inc. and Xenomics. Dr. Sidransky is a founder of several private biotechnology companies and has served on numerous scientific advisory boards of both private and public companies, including Medimmune, Telik, Roche and Amgen. He was formerly on the board of scientific counselors at the National Institute of Dental and Craniofacial Research and is a member of the Recombinant DNA advisory committee at the National Institutes of Health. Dr. Sidransky sits on numerous editorial boards and has served as senior editor of several cancer-related journals. He is certified in internal medicine and medical oncology by the American Board of Medicine.

"We are excited to have Dr. Lau and Dr. Sidransky join Morria's board," said Mark Cohen, chairman of the board. "Their extensive pharmaceutical and corporate experience will provide valuable guidance in both our clinical development plan with our lead anti-inflammatory compounds and the development of the company from a corporate perspective."


Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi- functional anti-inflammatory drugs (MFAIDs). The company's objective is to become a pivotal player in the anti-inflammatory drug market through the introduction of novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including skin, pulmonary and gastro- intestinal inflammatory diseases. For more information please visit

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - persons in the business of disseminating information.

SOURCE: Morria Biopharmaceuticals Plc

UK CONTACT: Yuval Cohen, President

53 Davies Street, London, W1K 5JH, United Kingdom

Tel: +44 (0) 207 152 6341 or

US CONTACT: Greg Tiberend

Richard Lewis Communications, Inc.

35 West 35 St., Suite 505, New York, NY 10001

Tel: +1 212-827-0020 or

SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):